Plain-English translation of NCT05719714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This 6-month study is testing whether a medication called dapagliflozin can help people with chronic kidney disease who also have subtle heart problems. Half of the participants will take the medication daily, while the other half will continue their usual care. Researchers will use heart imaging and exercise tests to see if the medication improves how the heart works.
Many people with chronic kidney disease develop heart problems that don't show obvious symptoms at first. This study wants to know whether this medication can prevent or slow down these hidden heart changes before they become serious.
You will visit the research center at the start and again after 6 months. At each visit, you'll have heart ultrasound imaging and an exercise stress test to measure your heart and lung function. Half of participants will take one tablet of the medication daily for the full 6 months, while the other half will continue with their regular treatment. Blood tests will also be done to look for chemical changes related to how your heart and kidneys are working.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
United States